JP6877771B2 - ピロリジン誘導体 - Google Patents
ピロリジン誘導体 Download PDFInfo
- Publication number
- JP6877771B2 JP6877771B2 JP2018541471A JP2018541471A JP6877771B2 JP 6877771 B2 JP6877771 B2 JP 6877771B2 JP 2018541471 A JP2018541471 A JP 2018541471A JP 2018541471 A JP2018541471 A JP 2018541471A JP 6877771 B2 JP6877771 B2 JP 6877771B2
- Authority
- JP
- Japan
- Prior art keywords
- azabicyclo
- hexane
- ylethynyl
- aryl
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C(C1C*C2)C12C#CC1=NC=CCC1 Chemical compound C(C1C*C2)C12C#CC1=NC=CCC1 0.000 description 10
- YJSKSHQVHGOSQN-UHFFFAOYSA-N C(C1CNC2)C12C#Cc1ncccc1 Chemical compound C(C1CNC2)C12C#Cc1ncccc1 YJSKSHQVHGOSQN-UHFFFAOYSA-N 0.000 description 4
- CQXZSEXZQVKCHW-UHFFFAOYSA-N N#Cc1cc(F)cc(F)c1 Chemical compound N#Cc1cc(F)cc(F)c1 CQXZSEXZQVKCHW-UHFFFAOYSA-N 0.000 description 2
- HDHOKSYAKLYHJG-UHFFFAOYSA-N C(C1CN(C2)c3ccccc3)C12C#Cc1ncccc1 Chemical compound C(C1CN(C2)c3ccccc3)C12C#Cc1ncccc1 HDHOKSYAKLYHJG-UHFFFAOYSA-N 0.000 description 1
- RPZHPWURURGYOD-UHFFFAOYSA-N C(C1CNC2)C12C#Cc1ncccn1 Chemical compound C(C1CNC2)C12C#Cc1ncccn1 RPZHPWURURGYOD-UHFFFAOYSA-N 0.000 description 1
- MPHIHGXCNSORCD-UHFFFAOYSA-N C(C1CNC2)C12C#Cc1nnccc1 Chemical compound C(C1CNC2)C12C#Cc1nnccc1 MPHIHGXCNSORCD-UHFFFAOYSA-N 0.000 description 1
- WTDIJNNBKDIOIQ-UHFFFAOYSA-N C=[Br]c1ncccc1 Chemical compound C=[Br]c1ncccc1 WTDIJNNBKDIOIQ-UHFFFAOYSA-N 0.000 description 1
- AGKAYQWMUSFFPK-UHFFFAOYSA-N CC(C)(C)OC(N(CC1C2)CC12C#C)=O Chemical compound CC(C)(C)OC(N(CC1C2)CC12C#C)=O AGKAYQWMUSFFPK-UHFFFAOYSA-N 0.000 description 1
- IPSNJHKXIXHUKQ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1C2)CC12C#Cc1ncccc1)=O Chemical compound CC(C)(C)OC(N(CC1C2)CC12C#Cc1ncccc1)=O IPSNJHKXIXHUKQ-UHFFFAOYSA-N 0.000 description 1
- ILXSTFFHCNCLMT-UHFFFAOYSA-N Cc1nc(C#CC(C2)(C3)C2CN3C(C(C=CC2)=CC2Cl)O)c[s]1 Chemical compound Cc1nc(C#CC(C2)(C3)C2CN3C(C(C=CC2)=CC2Cl)O)c[s]1 ILXSTFFHCNCLMT-UHFFFAOYSA-N 0.000 description 1
- RBIZBPQPIFTKPW-UHFFFAOYSA-N Cc1nc(C#CC2(C3)C3CNC2)c[s]1 Chemical compound Cc1nc(C#CC2(C3)C3CNC2)c[s]1 RBIZBPQPIFTKPW-UHFFFAOYSA-N 0.000 description 1
- UFCMTQUQWOJROL-UHFFFAOYSA-N Fc(cc(cc1)N(CC2C3)CC23C#Cc2ccccn2)c1Cl Chemical compound Fc(cc(cc1)N(CC2C3)CC23C#Cc2ccccn2)c1Cl UFCMTQUQWOJROL-UHFFFAOYSA-N 0.000 description 1
- VNMRRTIDEYNZOV-UHFFFAOYSA-N Fc1cc(I)ccc1Cl Chemical compound Fc1cc(I)ccc1Cl VNMRRTIDEYNZOV-UHFFFAOYSA-N 0.000 description 1
- UEVBJKDMTCVLPL-UHFFFAOYSA-N N#CCC(CC(F)=C1)=CC=C1N(CC1C2)CC12C#Cc1nccnc1 Chemical compound N#CCC(CC(F)=C1)=CC=C1N(CC1C2)CC12C#Cc1nccnc1 UEVBJKDMTCVLPL-UHFFFAOYSA-N 0.000 description 1
- STXAVEHFKAXGOX-UHFFFAOYSA-N N#Cc1cc(Br)ccc1 Chemical compound N#Cc1cc(Br)ccc1 STXAVEHFKAXGOX-UHFFFAOYSA-N 0.000 description 1
- MYRISJLONLWHHS-UHFFFAOYSA-N N#Cc1cc(N(CC2C3)CC23C#Cc2ccccn2)cc(F)c1 Chemical compound N#Cc1cc(N(CC2C3)CC23C#Cc2ccccn2)cc(F)c1 MYRISJLONLWHHS-UHFFFAOYSA-N 0.000 description 1
- IKUDBSKONSPSTH-UHFFFAOYSA-N N#Cc1cc(N(CC2C3)CC23C#Cc2ncccn2)ccc1 Chemical compound N#Cc1cc(N(CC2C3)CC23C#Cc2ncccn2)ccc1 IKUDBSKONSPSTH-UHFFFAOYSA-N 0.000 description 1
- WHIHIKVIWVIIER-UHFFFAOYSA-N O=C(c1cc(Cl)ccc1)Cl Chemical compound O=C(c1cc(Cl)ccc1)Cl WHIHIKVIWVIIER-UHFFFAOYSA-N 0.000 description 1
- SYVNVEGIRVXRQH-UHFFFAOYSA-N O=C(c1cc(F)ccc1)Cl Chemical compound O=C(c1cc(F)ccc1)Cl SYVNVEGIRVXRQH-UHFFFAOYSA-N 0.000 description 1
- SRKDGOFYDUMUQM-UHFFFAOYSA-N O=C(c1cccc(F)c1)N(CC1C2)CC12C#Cc1ncccc1 Chemical compound O=C(c1cccc(F)c1)N(CC1C2)CC12C#Cc1ncccc1 SRKDGOFYDUMUQM-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N O=C(c1ccccc1)Cl Chemical compound O=C(c1ccccc1)Cl PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N O=S(c1ccccc1)(Cl)=O Chemical compound O=S(c1ccccc1)(Cl)=O CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- UYTXNBPVMVNBSF-UHFFFAOYSA-N O=S(c1ccccc1)(N(CC1C2)CC12C#Cc1ncccc1)=O Chemical compound O=S(c1ccccc1)(N(CC1C2)CC12C#Cc1ncccc1)=O UYTXNBPVMVNBSF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510713865.7A CN106632243B (zh) | 2015-10-28 | 2015-10-28 | 吡咯烷衍生物 |
| CN201510713865.7 | 2015-10-28 | ||
| PCT/CN2016/102946 WO2017071536A1 (en) | 2015-10-28 | 2016-10-21 | Pyrrolidine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018532778A JP2018532778A (ja) | 2018-11-08 |
| JP2018532778A5 JP2018532778A5 (enExample) | 2019-12-05 |
| JP6877771B2 true JP6877771B2 (ja) | 2021-05-26 |
Family
ID=58629839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541471A Active JP6877771B2 (ja) | 2015-10-28 | 2016-10-21 | ピロリジン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10328054B2 (enExample) |
| EP (1) | EP3371163B1 (enExample) |
| JP (1) | JP6877771B2 (enExample) |
| KR (1) | KR102815874B1 (enExample) |
| CN (2) | CN106632243B (enExample) |
| AU (1) | AU2016345244B2 (enExample) |
| BR (1) | BR112018008204B1 (enExample) |
| CA (1) | CA3000794C (enExample) |
| DK (1) | DK3371163T3 (enExample) |
| ES (1) | ES2922978T3 (enExample) |
| HU (1) | HUE058899T2 (enExample) |
| IL (1) | IL258517B (enExample) |
| MX (1) | MX385587B (enExample) |
| RU (1) | RU2740019C1 (enExample) |
| TW (1) | TWI725998B (enExample) |
| WO (1) | WO2017071536A1 (enExample) |
| ZA (1) | ZA201802235B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015051244A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3119397B1 (en) | 2014-03-19 | 2022-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| CN114230571B (zh) | 2015-09-14 | 2025-07-08 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
| CN106632243B (zh) * | 2015-10-28 | 2019-03-15 | 华领医药技术（上海）有限公司 | 吡咯烷衍生物 |
| KR102740618B1 (ko) * | 2021-11-17 | 2024-12-10 | 유노비아 주식회사 | 아이속사졸 유도체의 제조 방법 및 그의 중간체 |
| CN119569744A (zh) * | 2024-11-19 | 2025-03-07 | 武汉大学人民医院（湖北省人民医院） | 吡喃吡啶酮生物碱类化合物及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0503646D0 (en) * | 2005-02-22 | 2005-03-30 | Novartis Ag | Organic compounds |
| CN101990536B (zh) * | 2008-01-18 | 2014-09-03 | 上海靶点药物有限公司 | 基于吡咯烷的化合物 |
| TW201116532A (en) * | 2009-08-05 | 2011-05-16 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| WO2012152854A1 (en) * | 2011-05-12 | 2012-11-15 | Merz Pharma Gmbh & Co. Kgaa | Metabotropic glutamate receptor modulators |
| UA110862C2 (uk) * | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
| WO2014124560A1 (en) * | 2013-02-18 | 2014-08-21 | Hua Medicine (Shanghai) Ltd. | Mglur regulators |
| CN106632243B (zh) * | 2015-10-28 | 2019-03-15 | 华领医药技术（上海）有限公司 | 吡咯烷衍生物 |
-
2015
- 2015-10-28 CN CN201510713865.7A patent/CN106632243B/zh active Active
-
2016
- 2016-10-21 WO PCT/CN2016/102946 patent/WO2017071536A1/en not_active Ceased
- 2016-10-21 US US15/771,920 patent/US10328054B2/en active Active
- 2016-10-21 CA CA3000794A patent/CA3000794C/en active Active
- 2016-10-21 JP JP2018541471A patent/JP6877771B2/ja active Active
- 2016-10-21 RU RU2018119038A patent/RU2740019C1/ru active
- 2016-10-21 DK DK16858971.1T patent/DK3371163T3/da active
- 2016-10-21 BR BR112018008204-0A patent/BR112018008204B1/pt active IP Right Grant
- 2016-10-21 CN CN201680062993.2A patent/CN108349935B/zh active Active
- 2016-10-21 ES ES16858971T patent/ES2922978T3/es active Active
- 2016-10-21 EP EP16858971.1A patent/EP3371163B1/en active Active
- 2016-10-21 HU HUE16858971A patent/HUE058899T2/hu unknown
- 2016-10-21 KR KR1020187014851A patent/KR102815874B1/ko active Active
- 2016-10-21 AU AU2016345244A patent/AU2016345244B2/en active Active
- 2016-10-21 MX MX2018004868A patent/MX385587B/es unknown
- 2016-10-27 TW TW105134694A patent/TWI725998B/zh active
-
2018
- 2018-04-05 IL IL258517A patent/IL258517B/en active IP Right Grant
- 2018-04-05 ZA ZA2018/02235A patent/ZA201802235B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK3371163T3 (da) | 2022-07-04 |
| KR102815874B1 (ko) | 2025-06-02 |
| EP3371163B1 (en) | 2022-03-30 |
| RU2740019C1 (ru) | 2020-12-30 |
| IL258517B (en) | 2020-05-31 |
| EP3371163A1 (en) | 2018-09-12 |
| KR20180070693A (ko) | 2018-06-26 |
| IL258517A (en) | 2018-05-31 |
| JP2018532778A (ja) | 2018-11-08 |
| US10328054B2 (en) | 2019-06-25 |
| EP3371163A4 (en) | 2019-05-01 |
| BR112018008204A2 (pt) | 2018-12-18 |
| AU2016345244B2 (en) | 2020-07-09 |
| ES2922978T3 (es) | 2022-09-22 |
| CA3000794C (en) | 2024-01-16 |
| US20180318254A1 (en) | 2018-11-08 |
| CN106632243A (zh) | 2017-05-10 |
| CN108349935B (zh) | 2021-02-05 |
| HK1254456A1 (en) | 2019-07-19 |
| TW201718542A (zh) | 2017-06-01 |
| CN108349935A (zh) | 2018-07-31 |
| CN106632243B (zh) | 2019-03-15 |
| MX385587B (es) | 2025-03-18 |
| MX2018004868A (es) | 2018-11-09 |
| WO2017071536A1 (en) | 2017-05-04 |
| HUE058899T2 (hu) | 2022-09-28 |
| BR112018008204B1 (pt) | 2023-12-26 |
| CA3000794A1 (en) | 2017-05-04 |
| AU2016345244A1 (en) | 2018-04-26 |
| TWI725998B (zh) | 2021-05-01 |
| ZA201802235B (en) | 2019-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6877771B2 (ja) | ピロリジン誘導体 | |
| JP7609854B2 (ja) | Ｍａｇｌ阻害剤としての４，４ａ，５，７，８，８ａ－ヘキサピリド［４，３－ｂ］［１，４］オキサジン－３－オン化合物 | |
| JP6461803B2 (ja) | 置換ベンゼン化合物 | |
| KR100862879B1 (ko) | Ｈｉｖ 인테그라제의 ｎ-치환된 하이드록시피리미디논 카복스아미드 억제제 | |
| RU2425826C2 (ru) | СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ ITPKb | |
| RS61448B1 (sr) | Način pripreme derivata oksazolo [4,5-b] piridina i tiazolo [4,5-b] piridina kao irak4 inhibitora za lečenje raka | |
| HK1231480A1 (zh) | 作为irak4抑制剂的吲唑化合物 | |
| JP2017522346A (ja) | ブロモドメインに対して活性な化合物 | |
| AU2007276433A1 (en) | Amino-piperidine derivatives as CETP inhibitors | |
| JPWO2004069824A1 (ja) | ピラゾール誘導体 | |
| JP2010523530A (ja) | タンパク質キナーゼ阻害剤として有益な［２，６］ナフチリジン | |
| WO2012036278A1 (ja) | グリシントランスポーター阻害物質 | |
| KR20100052507A (ko) | ｍＧｌｕ５ 길항제로서의 신규 헤테로 고리 화합물 | |
| KR20130143141A (ko) | 피라졸리딘-3-온 유도체 | |
| CN102482259B (zh) | 作为nk3受体拮抗剂的吡咯烷衍生物 | |
| TW202016090A (zh) | 經烷氧基取代之吡啶基衍生物 | |
| WO2014124560A1 (en) | Mglur regulators | |
| WO2017018475A1 (ja) | 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途 | |
| HK1254456B (en) | Pyrrolidine derivatives | |
| JP2024528614A (ja) | ニトリルｓｕｍｏ阻害剤及びその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191021 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191021 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201015 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201020 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210119 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210323 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210421 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6877771 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |